Long-term disease-free survival after autologous bone marrow transplantation in a primary plasma cell leukaemia: detection of minimal residual disease in the transplant marrow by third-complementarity-determining region-specific probes.
Primary plasma cell leukaemia (PPCL) is a rare form of plasma cell neoplasm. Treatments of PPCL have been most disappointing. A patient with PPCL received high-dose melphalan plus total body irradiation and autologous bone marrow transplantation (ABMT). By using third-complementarity-determining region (CDRIII)-specific probes, minimal residual disease (MRD) was detected in remission marrow, collected 1 month before ABMT. MRD was no longer detected by CDRIII-specific probes 6, 19 and 26 months after transplantation. The patient remained in complete remission up to 59 months after ABMT.
Yeh
K H
KH
Department of Oncology, National Taiwan University Hospital, Taipei, R.O.C.
Lin
M T
MT
Tang
J L
JL
Yang
C H
CH
Tsay
W
W
Chen
Y C
YC
D000328:Adult; D001483:Base Sequence; D016026:Bone Marrow Transplantation; D015342:DNA Probes; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007952:Leukemia, Plasma Cell / Q000628:therapy*; D008969:Molecular Sequence Data; D018365:Neoplasm, Residual / Q000175:diagnosis*; D014184:Transplantation, Homologous
D015342:DNA Probes